tradingkey.logo

Legend Biotech Corp <LEGN.OQ> expected to post a loss of 23 cents a share - Earnings Preview

ReutersMay 9, 2025 4:33 PM
  • Legend Biotech Corp LEGN.OQ LEGN.O is expected to show a rise in quarterly revenue when it reports results on May 13 for the period ending March 31 2025

  • The Somerset New Jersey-based company is expected to report a 106.0% increase in revenue to $193.619 million from $93.99 million a year ago, according to the mean estimate from 12 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Legend Biotech Corp is for a loss of 23 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 22 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts had risen by about 5.8% in the last three months. ​

  • Wall Street's median 12-month price target for Legend Biotech Corp is $80.00​, above​ its last closing price of $32.04. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.34

-0.33

0.08

Beat

123.9

Sep. 30 2024

-0.42

-0.44

-0.68

Missed

-55.1

Jun. 30 2024

-0.41

-0.38

-0.10

Beat

73.8​

Mar. 31 2024

-0.35

-0.34

-0.32

Beat

7.1

​​Dec. 31 2023

-0.94

-0.83

-0.80

Beat

3.6

Sep. 30 2023

-0.48

-0.68

-0.34

Beat

49.8​

Jun. 30 2023

-0.59

-0.60

-1.14

Missed

-90

Mar. 31 2023

-0.83

-0.78

-0.68

Beat

12.8

This summary was machine generated May 9 at 16:33 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles